Last reviewed · How we verify

Centro Cardiologico Monzino — Portfolio Competitive Intelligence Brief

Centro Cardiologico Monzino pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Furosemide and matched saline hydration Furosemide and matched saline hydration phase 3 Loop diuretic with intravenous fluid replacement Na-K-2Cl cotransporter (NKCC2) in the loop of Henle Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Centro Cardiologico Monzino:

Cite this brief

Drug Landscape (2026). Centro Cardiologico Monzino — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-cardiologico-monzino. Accessed 2026-05-17.

Related